Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-10-2014 | Original Article – Cancer Research

Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients

Authors: Verena Kirn, Rong Shi, Sabine Heublein, Julia Knabl, Margit Guenthner-Biller, Ulrich Andergassen, Claudius Fridrich, Wolfram Malter, Jan Harder, Klaus Friese, Doris Mayr, Udo Jeschke

Published in: Journal of Cancer Research and Clinical Oncology | Issue 10/2014

Abstract

Purpose

Ovarian carcinoma is the third most common gynecological cancer and only short recurrence-free survival and overall survival times are archived. The role of the estrogen receptor expression is well studied in breast cancer and breast cancer cell lines. Patients with positive estrogen receptor expression have a lower risk for recurrence and a better overall survival. Previous studies have shown that ESR1 methylation influences ovarian cancer development and might thus play a role regarding prognosis of ovarian carcinoma.

Methods

A total of 75 patients were identified that were treated for ovarian carcinoma by debulking surgery and adjuvant standard chemotherapy. Isolation and bisulfite treatment of genomic DNA from serial sections of surgically resected ovarian carcinoma tissue was performed using commercially available kits. For the detection of methylated ESR1 promoter sequences, real-time methylation-specific PCR was used.

Results

Promoter methylation did not show a correlation between clinical–pathological data for all patients. However, within the subgroup of low-grade ovarian carcinoma patients and patients with an ovarian tumor of low malignant potential methylation of the ESR1 promoter inversely correlated with survival (p = 0.031).

Conclusions

Although small numbers of ovarian carcinoma patients were analyzed, methylation status might be useful as a prognostic marker within the subgroup of low-grade ovarian carcinoma patients. Further studies should investigate a larger cohort and also address the use of demethylation agents with respect to improve patient’s prognosis in this subgroup of ovarian carcinoma patients.

Barton CA, Hacker NF, Clark SJ, O’ Brien PM (2008) DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment. Gynecol Oncol 109(1):129–139. doi:10.1016/j.ygyno.2007.12.017 PubMedCrossRef

Eads CA, Lord RV, Kurumboor SK, Wickramasinghe K, Skinner ML, Long TI, Peters JH, DeMeester TR, Danenberg KD, Danenberg PV, Laird PW, Skinner KA (2000) Fields of aberrant CpG island hypermethylation in Barrett’s esophagus and associated adenocarcinoma. Cancer Res 60:5021–5026PubMed

Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229PubMed

Feng Q, Deftereos G, Hawes SE, Stern JE, Willner JB, Swisher EM, Xi L, Drescher C, Urban N, Kiviat N (2008) DNA hypermethylation, Her/2-neu overexpression and p53 mutations in ovarian carcinoma. Gynecol Oncol 111(2):320–329. doi:10.1016/j.ygyno.2008.07.036 PubMedCrossRefPubMedCentral

Gross AL, Kurman RJ, Vang R, Shih IM, Visvanathan K (2010) Precursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol 2010:126295. doi:10.1155/2010/126295 PubMedCrossRefPubMedCentral

Harder J, Engelstaedter V, Usadel H, Lassmann S, Werner M, Baier P, Otto F, Varbanova M, Schaeffner E, Olschewski M, Blum HE, Opitz OG (2009) CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients. Br J Cancer 100(2):360–365. doi:10.1038/sj.bjc.6604859 PubMedCrossRefPubMedCentral

Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO, Laird PW (2012) DNA Methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS ONE 5(2):e9359. doi:10.1371/journal.pone.0009359 CrossRef

Huang YW, Jansen RA, Fabbri E, Potter D, Liyanarachchi S, Chan MW, Liu JC, Crijns AP, Brown R, Nephew KP, van der Zee AG, Cohn DE, Yan PS, Huang TH, Lin HJ (2009) Identification of candidate epigenetic biomarkers for ovarian cancer detection. Oncol Rep 22(4):853–861PubMedPubMedCentral

Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB (1994) Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 7(4):536–540PubMedCrossRef

Issa JP, Zehnbauer BA, Civin CI, Collector MI, Sharkis SJ, Davidson NE, Kaufmann SH, Baylin SB (1996) The estrogen receptor CpG island is methylated in most hematopoietic neoplasms. Cancer Res 56(5):973–977PubMed

Kurman RJ, Shih IM (2010) The origin and pathogenesis of epithelial ovarian cancer—a proposed unifying theory. Am J Surg Pathol 34(3):433–443. doi:10.1097/PAS.0b013e3181cf3d79 PubMedCrossRefPubMedCentral

Lapidus RG, Ferguson AT, Ottaviano YL, Parl FE, Smith HS, Weitzman SA, Baylin SB, Issa JP, Davidson NE (1996) Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors. Clin Cancer Res 2(5):805–810PubMed

Lapidus RG, Nass SJ, Davidson NE (1998a) The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3(1):85–94PubMedCrossRef

Lapidus RG, Nass SJ, Butash KA, Parl FF, Weitzman SA, Graff JG, Herman JG, Davidson NE (1998b) Mapping of ER gene CpG island methylation-specific polymerase chain reaction. Cancer Res 58(12):2515–2519PubMed

Lenhard M, Lennerova T, Heublein S, Ditsch N, Himsl I, Mayr D, Friese K, Jeschke U (2012) Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patient survival. BMC Cancer 12:553PubMedCrossRefPubMedCentral

McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. New Eng J Med 334:1–6PubMedCrossRef

Montavon C, Glos BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, Hacker NF, Sutherland RL, Clark SJ, O‘Brien PM (2012) Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 124:582–588. doi:10.1016/j.ygyno.2011.11.026 PubMedCrossRef

Newcomb PA, Longnecker MP, Storer BE, Mittendorf R, Baron J, Clapp RW, Bogdan G, Willett WC (1995) Long-term hormone replacement therapy and risk of breast cancer in postmenopausal women. Am J Epidemiol 142(8):788–795PubMed

O’Doherty AM, Church SW, Russel SE, Nelson J, Hickey I (2002) Methylation status of oestrogen receptor alpha gene promoter sequence in human ovarian epithelial cell lines. Br J Cancer 86(2):282–284PubMedCrossRefPubMedCentral

Shaw D, Clamp A, Jayson GC (2013) Angiogenesis as a target for the treatment of ovarian cancer. Curr Opin Oncol 25(5):558–565PubMedCrossRef

Shi IM, Chen L, Wang C, Gu J, Davidson B, Cope L, Kurman RJ, Xuan J, Wang TL (2010) Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis. Am J Obstet Gynecol 203(6):584.e1–584.e22. doi:10.1016/j.ajog.2010.08.003

Su HY, Lai HC, Lin YW, Chou YC, Liu CY, Yu MH (2009) An epigenetic marker panel for screening and prognostic prediction of ovarian cancer. Int J Cancer 124(2):387–393. doi:10.1002/ijc.23957 PubMedCrossRef

Teodoridis JM, Hall J, Marsh S, Kannall HD, Smyth C, Curto J, Siddiqui N, Gabra H, McLeod HL, Strathdee G, Brown R (2005) CpG Island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res 65(19):8961–8967PubMedCrossRef

Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ, Widschwendter M (2009) An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS ONE 4(12):e8274. doi:10.1371/journal.pone.0008274 PubMedCrossRefPubMedCentral

Vang R, Shih IM, Kurman RJ (2009) Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol 16(5):267–282. doi:10.1097/PAP.0b013e3181b4fffa PubMedCrossRefPubMedCentral

Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL (2008) DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 1:47. doi:10.1186/1755-8794-1-47 PubMedCrossRefPubMedCentral

Wei SH, Balch C, Paik HH, Kim YS, Baldwin RL, Liyanarchchi S, Li L, Wang Z, Wan JC, Davuluri RV, Karlan BY, Gifford G, Brown R, Kim S, Huang TH, Nephew KP (2006) Prognostik DNA methylation biomarkers in ovarian cancer. Clin Cancer Res 12(9):2788–2794PubMedCrossRef

Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D, Yu H (2006) Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107(2):299–308PubMedCrossRef

Wrzeszczynski KO, Varadan V, Byrnes J, Lum E, Kamalakaran S, Levine DA, Dimitrova N, Zhang MQ, Lucito R (2011) Identification of tumor suppressors and oncogenes from genomic and epigenetic features in ovarian cancer. PLoS ONE 6(12):e28503. doi:10.1371/journal.pone.0028503 PubMedCrossRefPubMedCentral

Yang HJ, Liu VWS, Wang Y, Tsang PC, Ngan HY (2006) Differential DNA methylation profiles in gynecological cancers and correlation with clinic-pathological data. BMC Cancer 6:212PubMedCrossRefPubMedCentral

Yap OWS, Bhat G, Liu L, Tollefsbol TO (2009) Epigenetic modifications of the estrogen receptor β gene in epithelial ovarian cancer cells. Anticancer Res 29(1):139–144PubMedPubMedCentral

Title: Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients
Authors: Verena Kirn
Rong Shi
Sabine Heublein
Julia Knabl
Margit Guenthner-Biller
Ulrich Andergassen
Claudius Fridrich
Wolfram Malter
Jan Harder
Klaus Friese
Doris Mayr
Udo Jeschke
Publication date: 01-10-2014
Publisher: Springer Berlin Heidelberg
Published in: Journal of Cancer Research and Clinical Oncology / Issue 10/2014
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1729-9

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Estrogen receptor promoter methylation predicts survival in low-grade ovarian carcinoma patients

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2014

A cisplatin-resistant head and neck cancer cell line with cytoplasmic p53mut exhibits ATP-binding cassette transporter upregulation and high glutathione levels

Integrative metabolome and transcriptome profiling reveals discordant glycolysis process between osteosarcoma and normal osteoblastic cells

Identification of proteins associated with lymph node metastasis of gastric cancer

YM155 reverses rapamycin resistance in renal cancer by decreasing survivin

Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer

miR-23a-mediated migration/invasion is rescued by its target, IRS-1, in non-small cell lung cancer cells

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page